Loading...
Loading...
FDMT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1.6M |
| Gross Profit | -1.6M |
| Operating Expense | 40.8M |
| Operating I/L | -42.5M |
| Other Income/Expense | 7.5M |
| Interest Income | 7.5M |
| Pretax | -35.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -35.0M |
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company specializing in the development of product candidates using adeno-associated viruses vectors. The company's portfolio focuses on gene therapy product candidates in ophthalmology, cardiology, and pulmonology. It has three product candidates in clinical trials, including 4D-125 for X-linked retinitis pigmentosa, 4D-110 for choroideremia, and 4D-310 for Fabry disease. Additionally, it has two IND candidates, 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. also has research and collaboration arrangements with uniQure, CRF, Roche, and CFF.
